Compare Bristol-Myers Squibb Co (BMY) vs Iris Energy Limited (IREN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Iris Energy Limited — how do they compare? Bristol-Myers Squibb Co trades at $63.79 (market cap $129.94B), while Iris Energy Limited trades at $43.84 (market cap $14.20B). The key difference: Bristol-Myers Squibb Co is far larger — about 9.2× Iris Energy Limited's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals.
| BMY | IREN | |
|---|---|---|
Market Cap | $129.94B | $14.20B |
Sector | Health | Energy |
52-Week High | $65.89 | $76.41 |
52-Week Low | $42.60 | $17.73 |
Enterprise Value | $163.92B | $15.95B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
IREN stock trades at $43.17, up 11.44% today amid positive AI infrastructure news. The technical picture is neutral with resistance near $42. Fundamentally, the company shows strong revenue growth to $501M in 2025 and has secured $2.8B in new AI contracts, though it has missed recent EPS estimates and reports negative ROE and ROA. Analyst sentiment is bullish with a $84.43 price target.
Outlook is driven by AI cloud expansion but carries execution risks. The stock offers growth potential from its $4B revenue target, yet high valuations and recent earnings misses pose challenges. Investors should weigh contract momentum against profitability concerns and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
